5-(Piperidin-4-yl)-3-(pyridin-4-yl)-1,2,4-oxadiazole

Catalog No. :
ACBWPL978
CAS No. :
276237-03-7
Molecular Formula :
C12H14N4O
Molecular Weight :
230.27

IUPAC Name:5-(piperidin-4-yl)-3-(pyridin-4-yl)-1,2,4-oxadiazole

5-(Piperidin-4-yl)-3-(pyridin-4-yl)-1,2,4-oxadiazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$55.00Login to see priceIn stockIn stock
250mg95%$93.00Login to see priceIn stockIn stock
1g95%$252.00Login to see priceIn stockIn stock
5g95%$1010.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-(Piperidin-4-yl)-3-(pyridin-4-yl)-1,2,4-oxadiazole
IUPAC Name5-(piperidin-4-yl)-3-(pyridin-4-yl)-1,2,4-oxadiazole
MDL No.MFCD03426075
Molecular FormulaC12H14N4O
Molecular Weight230.27
SMILESC1(C2=NOC(C3CCNCC3)=N2)=CC=NC=C1
InChI KeyOAAGDVLVOKMRCQ-UHFFFAOYSA-N
Synonym4-[3-(Pyridin-4-yl)-1,2,4-oxadiazol-5-yl]piperidine, 5-(Piperidin-4-yl)-3-(pyridin-4-yl)-1,2,4-oxadiazole;4-[5-(Piperidin-4-yl)-1,2,4-oxadiazol-3-yl]pyridine 95+%;Pyridine, 4-[5-(4-piperidinyl)-1,2,4-oxadiazol-3-yl]-
CAS No.276237-03-7
PubChem CID2761143

Safety Data

Pictogram
Toxic
Signal Word
Gefahr
Hazard Statement(s)
H301
Precautionary Statement(s)
P301+P310

Synthetic Route by SureRoute

1. ACBWPL978 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACBWPL978 route product structure diagram
    ACBWPL978276237-03-7 In Stock
Inquiry

2. ACBWPL978 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Plus
  5. ACBAUS147 route compound structure diagram
    ACBAUS1472923-16-2 In Stock
  6. Then
  7. ACBWPL978 route product structure diagram
    ACBWPL978276237-03-7 In Stock
Inquiry

Comments (0)